Company Also Names Christopher Horvath, D.V.M., as Vice President of Preclinical Sciences and Marie Green, Ph.D., as Senior Program Executive
CAMBRIDGE, Mass., Dec. 1 /PRNewswire/ -- Taligen Therapeutics Inc. today expanded its Cambridge, Mass.-based executive team with the appointment of Jeffrey T. Walsh as chief business officer. The company also announced the additions of Christopher Horvath, D.V.M., as vice president of preclinical sciences and Marie Green, Ph.D., as senior program executive.
The executive appointments reflect the advancement of Taligen's corporate growth plan, which Taligen initiated in August with the hiring of Abbie Celniker, Ph.D., as chief executive officer. Taligen is focused on building its preclinical, CMC and clinical development operations in Cambridge while maintaining early research activities in the laboratory of Michael Holers, M.D., in Denver.
"I am pleased that Taligen has been able to attract the level of talent and experience that Mr. Walsh, Dr. Horvath and Dr. Green bring to the company," said Celniker. "We now have in place most of the key executives we believe are necessary to advance our lead clinical candidates through preclinical development to IND submission and to continue to advance Taligen's growth plan."
Walsh, will contribute to the development of the company's overall business strategy and oversee finance, legal, business development and general business operations. He has spent more than 20 years in leadership roles in the pharmaceutical and biotechnology industries with a focus on corporate finance, strategic planning and business development while at Inotek Pharmaceuticals Corp., Exact Sciences Corp., Pathogenesis Corp. (now part of Novartis), and SmithKline Beecham (now part of GlaxoSmithKline).
"I am looking forward to working with Dr. Celniker and the rest of the team that she has assembled as we
|SOURCE Taligen Therapeutics Inc.|
Copyright©2008 PR Newswire.
All rights reserved